Cytokine-mediated signalling and early defects in lymphoid development

Current Opinion in Allergy and Clinical Immunology

Volumn 5, Issue 6, 2005, Pages 519-524

  Giliani, Silvia ^a   Mella, Patrizia ^a   Savoldi, Gianfranco ^a   Mazzolari, Evelina ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

IL7R; JAK3; SCID; c

Indexed keywords

CYTOKINE; DRUG CARRIER; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 7; INTERLEUKIN 7 RECEPTOR; JANUS KINASE 3; JANUS KINASE INHIBITOR; RECOMBINANT DNA; RETROVIRUS VECTOR; STAT PROTEIN;

ARTICLE; AUTOIMMUNE DISEASE; CELL MATURATION; CLINICAL TRIAL; COMBINED IMMUNODEFICIENCY; DEVELOPMENTAL DISORDER; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIARRHEA; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; ENTERITIS; GENE MUTATION; GENE THERAPY; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; KIDNEY FAILURE; LYMPHANGIOGENESIS; LYMPHATIC SYSTEM DISEASE; MULTIPLE SCLEROSIS; MUTANT; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; RHEUMATOID ARTHRITIS; SIDE EFFECT; SIGNAL TRANSDUCTION; T LYMPHOCYTE; VIRAL GENE DELIVERY SYSTEM; VIRUS INFECTION; WART VIRUS; X CHROMOSOME LINKED DISORDER;

EID: 27944442386     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/01.all.0000191889.35516.b6     Document Type: Article

References (44)

1. Picard C, Casanova JL. Inherited disorders of cytokines. Curr Opin Pediatr 2004; 16:648-658. The most recent and comprehensive review on the topic.
2. Notarangelo L, Casanova JL, Fischer A, et al. Primary immunodeficiency diseases: An update. J Allergy Clin Immunol 2004; 114:677-687. The most recent PID classification.
3. Notarangelo LD, Mazzolari E, Forino C, Giliani S. Mechanisms of primary immunodeficiencies: From bed-side to bench and back. Drug Discovery Today 2004; 1:383-390.
4. Fischer A, Le Deist F, Hacein-Bey-Abina S, et al. Severe combined immunodeficiency: A model disease for molecular immunology and therapy. Immunol Rev 2005; 203:98-109. An excellent review on different forms of SCID and available curative measures.
5. Buckley RH. The multiple causes of human SCID. J Clin Invest 2004; 114:1409-1411.
6. Noguchi M, Yi H, Rosenblatt HM, et al. Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell 1993; 73:147-157.
7. O'Shea JJ, Pesu M, Borie DC, Changelian PS. A new modality for immunosuppression: Targeting the JAK/STAT pathway. Nat Rev Drug Discov 2004; 3:555-564. Mechanisms of action of γc cytokine and development of JAK3 antagonist are very well reviewed.
8. Macchi P, Villa A, Giliani S, et al. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 1995; 377:65-68.
9. Russell SM, Tayebi N, Nakajima H, et al. Mutation of Jak3 in a patient with SCID: Essential role of Jak3 in lymphoid development. Science 1995; 270:797-800.
10. O'Shea JJ, Husa M, Li D, et al. Jak3 and the pathogenesis of severe combined immunodeficiency. Mol Immunol 2004; 41:727-737.
11. Pesu M, Candotti F, Husa M, et al. Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs. Immunol Rev 2005; 203:127-142. The most complete review on all aspects of JAK3 deficiency.
12. Giliani S, Mori L, de Saint Basile G, et al. Interleukin-7 receptor alpha (IL-7Ralpha) deficiency: Cellular and molecular bases - Analysis of clinical, immunological, and molecular features in 16 novel patients. Immunol Rev 2005; 203:110-126.
13. Buckley RH. Molecular defects in human severe combined immunodeficiency and approaches to immune reconstitution. Annu Rev Immunol 2004; 22:625-655. The most comprehensive review on different kind of human SCIDs with clinical, immunological and molecular features. Particularly interesting is the analysis on the therapeutic options.
14. Jo EK, Kook H, Uchiyama T, et al. Characterization of a novel nonsense mutation in the interleukin-7 receptor alpha gene in a Korean patient with severe combined immunodeficiency. Int J Hematol 2004; 80:332-335.
15. Goetz CA, Harmon IR, O'Neil JJ, et al. STAT5 activation underlies IL7 receptor-dependent B cell development. J Immunol 2004; 172:4770-4778.
16. Mestas J, Hughes CCW. Of mice and not men: Differences between mouse and human immunology. J Immunol 2004; 172:2731-2738. An interesting review which gives the bases for cautious interpretation of preclinical data obtained in mice.
17. Lodolce JP, Boone DL, Chai S, et al. IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity 1998; 9:669-676.
18. Lodolce JP, Burkett PR, Koka RM, et al. Regulation of lymphoid homeostasis by interleukin-15. Cytokine Growth Factor Rev 2002; 13:429-439.
19. Rakesh K, Agrawal DK, Rakesh K, Agrawal DK. Controlling cytokine signalling by constitutive inhibitors. Biochem Pharmacol 2005 [Epub ahead of print]. A review on the different classes of cytokines' signal transduction inhibitors.
20. Mitchell TJ, John S. Signal transducer and activator of transcription (STAT) signalling and T-cell lymphomas. Immunology 2005; 114:301-312. An excellent review on STAT protein function and regulation, particularly focused on their role in tumoural transformation.
21. Paukku K, Silvennoinen O. STATs as critical mediators of signal transduction and transcription: Lessons learned from STAT5. Cytokine Growth Factor Rev 2004; 15:435-455. This review describes in detail transcriptional activation and regulation of STAT proteins.
22. Antoine C, Muller S, Cant A, et al. Long-term survival and transplantation of haematopoietic stem cells for immunodeficiencies: Report of the European experience 1968-99. Lancet 2003; 361:553-560.
23. Myers LA, Patel DD, Puck JM, Buckley RH. Hematopoietic stem cell transplantation for severe combined immunodeficiency in the neonatal period leads to superior thymic output and improved survival. Blood 2002; 99:872-878.
24. Mazzolari E, Moshous D, Forino C, et al. Hematopoietic stem cell transplantation in Omenn syndrome: A single-center experience. Bone Marrow Transplant 2005; 36:107-114.
25. Laffort C, Le Deist F, Favre M, et al. Severe cutaneous papillomavirus disease after haematopoietic stem cell transplantation in patients with severe combined immune deficiency caused by common γc cytokine receptor subunit or jak-3 kinase deficiency. Lancet 2004; 363:2051-2054. This is the first report of HPV susceptibility in patients with SCID due to γc and JAK3 defects.
26. Wengler GS, Lanfranchi A, Frusca T, et al. In-utero transplantation of parental CD34 haematopoietic progenitor cells in a patient with X-linked severe combined immunodeficiency (SCIDXI). Lancet 1996; 348:1484-1487.
27. Bartolome J, Porta F, Lanfranchi A, et al. B cell function after haploidentical in utero bone marrow transplantation in a patient with severe combined immunodeficiency. Bone Marrow Transplant 2002; 29:625-628.
28. Pirovano S, Notarangelo LD, Valotti M, et al. Mutations of the T-cell receptor constant region after in utero stem cell transplantation. Immunogenetics 2004; 56:214-219.
29. Pirovano S, Notarangelo LD, Malacarne F, et al. Reconstitution of T-cell compartment after in utero stem cell transplantation: Analysis of T-cell repertoire and thymic output. Haematologica 2004; 89:450-461.
30. Stephan V, Wahn V, Le Deist F, et al. Atypical X-linked severe combined immunodeficiency due to possible spontaneous reversion of the genetic defect in T cells. N Engl J Med 1996; 335:1563-1537.
31. Hacein-Bey-Abina S, Le Deist F, Carlier F, et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 2002; 346:1185-1193.
32. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302:415-419.
33. Chinen J, Puck JM. Perspectives of gene therapy for primary immunodeficiencies. Curr Opin Allergy Clin Immunol 2004; 4:523-527. This review describes ongoing gene therapy trials for primary immunodeficiencies.
34. Schmidt M, Hacein-Bey-Abina S, Wissler M, et al. Clonal evidence for the transduction of CD34+ cells with lymphomyeloid differentiation potential and self-renewal capacity in the SCID-X1 gene therapy trial. Blood 2005; 105:2699-2706. In this study, the authors demonstrate that CD34+ ex-vivo manipulation has no effect on self-renewal and lymphomyeloid potentiality of stem cells.
35. Gaspar HB, Parsley KL, Howe S, et al. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 2004; 364:2181-2187. This study confirms and extends previous evidence that gene therapy may fully correct the immunodeficiency of SCIDX1.
36. Ginn SL, Curtin JA, Kramer B, et al. Treatment of an infant with X-linked severe combined immunodeficiency (SCID-X1) by gene therapy in Australia. Med J Aust 2005; 182:458-463.
37. Thrasher AJ, Hacein-Bey-Abina S, Gaspar HB, et al. Failure of SCID-X1 gene therapy in older patients. Blood 2005; 105:4255-4257. This is the first study in which failure of gene therapy in two patients with CD34+ successfully transduced correlates with the recipients' age.
38. Urnov FD, Miller JC, Lee YL, et al. Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature 2005; 435:646-651. In this study, a really innovative technique was used in order to achieve homologous recombination. The technique was successfully applied in vitro to correct an IL2RG mutation.
39. Chan K, Puck JM. Development of population-based newborn screening for severe combined immunodeficiency. J Allergy Clin Immunol 2005; 115:391-398.
40. Alpdogan O, van den Brink MR. IL-7 and IL-15: Therapeutic cytokines for immunodeficiency. Trends Immunol 2005; 26:56-64. The review reports on recent findings regarding the effects of IL-7 and IL-15 on lymphopoiesis and their potential use for the treatment of immunodeficiencies.
41. Papageorgiou AC, Wikman LE. Is JAK3 a new drug target for immunomodulation-based therapies? Trends Pharmacol Sci 2004; 25:558-562. This article discusses JAK3 as a major target in the future drug-design efforts.
42. Boggon TJ, Li Y, Manley PW, Eck MJ. Crystal structure of the Jak3 kinase domain in complex with a staurosporine analogue. Blood 2005; 106:996-1002. First description of the crystal structure of JAK3; a detailed view of the active site will facilitate the development of specific inhibitors.
43. Changelian PS, Flanagan ME, Ball DJ, et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 2003; 302:875-878.
44. Borie DC, O'Shea JJ, Changelian PS. JAK3 inhibition, a viable new modality of immunosuppression for solid organ transplants. Trends Mol Med 2004; 10:532-541. This review focuses on JAK3 inhibition in organ transplantation.